Predict your next investment

HEALTHCARE | Medical Equipment & Supplies

See what CB Insights has to offer

Founded Year



Asset Sale | AssetsPurchased

Total Raised


About Europroteome

Developer of early diagnostic and prognostic tools, patient-specific therapeutics, and immune therapy for human epithelial cancers. The company applies convergent gene expression technologies, in particular proteomics and transcriptomics to human epithelial cancers (e.g. colon or lung cancer) in order to identify cancer-specific protein expression patterns (targets or markers) suited for clinical applications. After characterizing and validating these identified targets, the company offers these targets for co-development agreements with industrial clients and marketing partners.

Europroteome Headquarter Location

Neuendorfstrasse 24a

Hennigsdorf, 16761,


49 33 0220232 50

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.